Stockholm, Sweden — June 9, 2025 — SIGRID, a Swedish healthtech company known for its patented SiPore® mineral technology, announced significant clinical and commercial milestones for its flagship product, Glucose Stabiliser. Recent clinical trials and consumer studies highlight the product’s effectiveness in regulating blood sugar and controlling appetite without causing metabolic discomfort.
In a 14-day, placebo-controlled clinical trial involving 20 healthy adults aged 18 to 64, participants wore continuous glucose monitors while maintaining their usual diets. The study compared seven days on a placebo with seven days using Glucose Stabiliser. Results showed participants maintained optimal glucose levels significantly longer during the Glucose Stabiliser phase (p = 0.01) and experienced an 85% reduction in hypoglycemic events compared to placebo (p = 0.004), indicating improved metabolic stability.
Sana Alajmovic, SIGRID’s Co-founder and CEO, emphasized the clear impact of the product: “Participants remained in the optimal glucose range nearly 100% of the time during use, reflecting the immediate and measurable benefits our users feel.”
Supporting these findings, a U.S. consumer study of 152 customers reported strong real-world effects. Ninety-three percent felt fuller longer after meals, 89% experienced fewer snack cravings, and 92% of those with bloating found relief. These results reinforce Glucose Stabiliser’s role in appetite regulation and metabolic comfort.
On the commercial front, SIGRID reported robust growth in the U.S. market in May, marking its fifth consecutive month of expansion. Key metrics include a 41% increase in net sales from April, 18% growth in new customer sales, a 68% net margin driven by subscription revenue, and a 4% drop in customer acquisition costs. Advertising performance on Meta’s platforms also improved significantly.
Alajmovic noted, “Our clinical validation and strong market response position SIGRID for rapid and profitable growth.”
Glucose Stabiliser utilizes SiPore®, a patented food-grade mineral developed through 15 years of research in Sweden. It works in the gut to slow carbohydrate and fat breakdown, reducing glucose absorption rates. This supports steady energy levels, appetite control, and fewer post-meal energy crashes. The technology is backed by multiple clinical studies published in peer-reviewed journals.
Related Topics
